Clinical Outcome Assessment

FDA’s lesson for rare disease trials: the wrong measure can hide a drug signal

In rare disease trials, statistics cannot rescue a poorly chosen endpoint: if the COA misses what actually changes, the treatment signal can disappear into noise.